We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioTelemetry (BEAT) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
In the latest trading session, BioTelemetry (BEAT - Free Report) closed at $76.01, marking a -0.38% move from the previous day. This change lagged the S&P 500's 0.27% loss on the day. Meanwhile, the Dow lost 0.41%, and the Nasdaq, a tech-heavy index, added 0.09%.
Prior to today's trading, shares of the heart monitoring device maker had gained 9.8% over the past month. This has outpaced the Medical sector's gain of 3.32% and the S&P 500's gain of 6.26% in that time.
Wall Street will be looking for positivity from BEAT as it approaches its next earnings report date. This is expected to be February 21, 2019. The company is expected to report EPS of $0.42, up 31.25% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $103.02 million, up 12.29% from the year-ago period.
It is also important to note the recent changes to analyst estimates for BEAT. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. BEAT is holding a Zacks Rank of #2 (Buy) right now.
Looking at its valuation, BEAT is holding a Forward P/E ratio of 42.87. Its industry sports an average Forward P/E of 21.98, so we one might conclude that BEAT is trading at a premium comparatively.
Meanwhile, BEAT's PEG ratio is currently 4.29. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical Services stocks are, on average, holding a PEG ratio of 1.79 based on yesterday's closing prices.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 67, which puts it in the top 27% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BEAT in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BioTelemetry (BEAT) Dips More Than Broader Markets: What You Should Know
In the latest trading session, BioTelemetry (BEAT - Free Report) closed at $76.01, marking a -0.38% move from the previous day. This change lagged the S&P 500's 0.27% loss on the day. Meanwhile, the Dow lost 0.41%, and the Nasdaq, a tech-heavy index, added 0.09%.
Prior to today's trading, shares of the heart monitoring device maker had gained 9.8% over the past month. This has outpaced the Medical sector's gain of 3.32% and the S&P 500's gain of 6.26% in that time.
Wall Street will be looking for positivity from BEAT as it approaches its next earnings report date. This is expected to be February 21, 2019. The company is expected to report EPS of $0.42, up 31.25% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $103.02 million, up 12.29% from the year-ago period.
It is also important to note the recent changes to analyst estimates for BEAT. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. BEAT is holding a Zacks Rank of #2 (Buy) right now.
Looking at its valuation, BEAT is holding a Forward P/E ratio of 42.87. Its industry sports an average Forward P/E of 21.98, so we one might conclude that BEAT is trading at a premium comparatively.
Meanwhile, BEAT's PEG ratio is currently 4.29. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical Services stocks are, on average, holding a PEG ratio of 1.79 based on yesterday's closing prices.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 67, which puts it in the top 27% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BEAT in the coming trading sessions, be sure to utilize Zacks.com.